Dyslipidaemias, particularly elevated LDL-cholesterol, are a primary modifiable risk factor for atherosclerotic cardiovascular disease. Statins remain the cornerstone of pharmacological LDL reduction; PCSK9 inhibitors, inclisiran, and bempedoic acid provide substantial additional lowering in high-risk patients. Lp(a) reduction through antisense oligonucleotide therapy represents the most clinically significant emerging target in lipidology.
Loading articles...
